A phase I Study to Assess the Safety and Tolerability of MBF-362 in Healthy Women, and Preliminary Efficacy in Otherwise Healthy Women diagnosed with Primary Dysmenorrhea

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521809-40-00

Acronym

MBF-362CT-02

Enrollment

Registered

2025-08-12

Start date

2025-12-10

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhea

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026